WallStSmart

Ironwood Pharmaceuticals Inc (IRWD)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 975% more annual revenue ($3.18B vs $296.15M). UTHR leads profitability with a 41.9% profit margin vs 8.1%. UTHR trades at a lower P/E of 19.4x. UTHR earns a higher WallStSmart Score of 67/100 (B-).

IRWD

Hold

47

out of 100

Grade: D+

Growth: 3.3Profit: 6.0Value: 8.3Quality: 5.0

UTHR

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 9.0Value: 10.0Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRWDUndervalued (+36.8%)

Margin of Safety

+36.8%

Fair Value

$7.02

Current Price

$3.04

$3.98 discount

UndervaluedFair: $7.02Overvalued
UTHRUndervalued (+62.9%)

Margin of Safety

+62.9%

Fair Value

$1282.02

Current Price

$541.60

$740.42 discount

UndervaluedFair: $1282.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRWD0 strengths · Avg: 0/10

No standout strengths identified

UTHR4 strengths · Avg: 9.5/10
Profit MarginProfitability
41.9%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
45.0%10/10

Strong operational efficiency at 45.0%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
24.5%8/10

Earnings expanding 24.5% YoY

Areas to Watch

IRWD3 concerns · Avg: 2.3/10
Market CapQuality
$495.70M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Revenue GrowthGrowth
-47.3%2/10

Revenue declined 47.3%

UTHR1 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : IRWD

IRWD has a balanced fundamental profile.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.

Bear Case : IRWD

The primary concerns for IRWD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio.

Key Dynamics to Monitor

IRWD profiles as a value stock while UTHR is a mature play — different risk/reward profiles.

UTHR carries more volatility with a beta of 0.86 — expect wider price swings.

UTHR is growing revenue faster at 7.4% — sustainability is the question.

UTHR generates stronger free cash flow (173M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (67/100 vs 47/100), backed by strong 41.9% margins. IRWD offers better value entry with a 36.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ironwood Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?